Nothing Special   »   [go: up one dir, main page]

ZA200902638B - Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for diabetes - Google Patents

Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for diabetes

Info

Publication number
ZA200902638B
ZA200902638B ZA200902638A ZA200902638A ZA200902638B ZA 200902638 B ZA200902638 B ZA 200902638B ZA 200902638 A ZA200902638 A ZA 200902638A ZA 200902638 A ZA200902638 A ZA 200902638A ZA 200902638 B ZA200902638 B ZA 200902638B
Authority
ZA
South Africa
Prior art keywords
imidazolone
diabetes
hsd1 inhibitors
imidazolidinone derivatives
imidazolidinone
Prior art date
Application number
ZA200902638A
Other languages
English (en)
Inventor
Jean Ackermann
Kurt Amrein
Daniel Hunziker
Bernd Kuhn
Alexander V Mayweg
Werner Neidhart
Tadakatsu Takahashi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200902638B publication Critical patent/ZA200902638B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200902638A 2006-10-19 2009-04-16 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for diabetes ZA200902638B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06122591 2006-10-19

Publications (1)

Publication Number Publication Date
ZA200902638B true ZA200902638B (en) 2010-03-31

Family

ID=39259578

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902638A ZA200902638B (en) 2006-10-19 2009-04-16 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for diabetes

Country Status (18)

Country Link
US (1) US8129423B2 (xx)
EP (2) EP2308851A1 (xx)
JP (1) JP5079011B2 (xx)
KR (2) KR20110079776A (xx)
CN (1) CN101553474B (xx)
AR (1) AR063332A1 (xx)
AU (1) AU2007312391B2 (xx)
BR (1) BRPI0717657A2 (xx)
CA (1) CA2666489C (xx)
CL (1) CL2007002972A1 (xx)
IL (1) IL197955A0 (xx)
MX (1) MX2009003939A (xx)
NO (1) NO20091548L (xx)
PE (1) PE20080890A1 (xx)
RU (1) RU2439062C2 (xx)
TW (1) TWI339120B (xx)
WO (1) WO2008046758A2 (xx)
ZA (1) ZA200902638B (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308851A1 (en) 2006-10-19 2011-04-13 F. Hoffmann-La Roche AG Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes
KR101176699B1 (ko) 2006-10-19 2012-08-23 에프. 호프만-라 로슈 아게 아미노메틸-4-이미다졸
JP5486928B2 (ja) * 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
EP2291371B1 (en) * 2008-05-01 2015-06-10 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20110002492A (ko) * 2008-05-01 2011-01-07 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
JP5538365B2 (ja) * 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
JP5451752B2 (ja) * 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
MX2011000175A (es) * 2008-06-25 2011-06-27 Envivo Pharmaceuticals Inc Compuestos heterociclicos 1,2-di-substituidos.
WO2010010157A2 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
CN102119160B (zh) * 2008-07-25 2014-11-05 贝林格尔·英格海姆国际有限公司 11β-羟基类固醇脱氢酶1的环状抑制剂
CN102105454A (zh) 2008-07-25 2011-06-22 贝林格尔.英格海姆国际有限公司 合成1型11β-羟基类固醇脱氢酶的抑制剂
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
TWI531571B (zh) 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2576570A1 (en) 2010-05-26 2013-04-10 Boehringer Ingelheim International GmbH 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011325286B2 (en) 2010-11-02 2015-04-16 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
JP2015157764A (ja) * 2012-06-14 2015-09-03 大正製薬株式会社 グリシントランスポーター阻害物質
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
EP3030562B1 (de) 2013-08-08 2017-07-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung
WO2015124544A1 (de) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
GB201416346D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2016087343A1 (de) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
US10174021B2 (en) 2014-12-02 2019-01-08 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-A]pyridines and their use
JP2018505885A (ja) 2015-02-05 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］−ピリジン−３−カルボキサミドおよびその使用
CA3011176C (en) 2016-01-13 2023-09-19 Grunenthal Gmbh 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PL3402784T3 (pl) 2016-01-13 2020-09-21 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu
EP3402783B1 (en) 2016-01-13 2020-03-04 Grünenthal GmbH 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
BR112018014296B1 (pt) 2016-01-13 2023-10-31 Grünenthal GmbH Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CA3011182A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
RU2746423C2 (ru) * 2019-09-02 2021-04-13 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL24005A (en) * 1964-12-31 1970-05-21 Robins Co Inc A H 1,3-disubstituted-4-(2-substituted-ethyl)-2-imidazolidinones,processes for their production and pharmaceutical compositions containing them
GB1175820A (en) 1966-02-18 1969-12-23 Upjohn Co Amino-Adamantane Derivatives
US3625956A (en) * 1967-12-08 1971-12-07 Ciba Geigy Corp 1-phenyl-4-alkyl-2-imidazolone derivatives
CH547288A (de) * 1971-06-23 1974-03-29 Ciba Geigy Ag Verfahren zur herstellung neuer heterocyclischer stoffe.
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
US5861420A (en) * 1991-04-05 1999-01-19 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
TW218017B (xx) * 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
WO2002020493A2 (en) * 2000-09-06 2002-03-14 Chugai Seiyaku Kabushiki Kaisha A traceless solid-phase synthesis of 2-imidazolones
AU2003256755A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
MXPA06012929A (es) * 2004-05-07 2007-01-26 Janssen Pharmaceutica Nv Derivados de adamantil pirrolidin-2-ona como inhibidores de 11-beta hidroxiesteroide deshidrogenasa.
MY141198A (en) * 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
JP5078621B2 (ja) * 2005-01-05 2012-11-21 アボット・ラボラトリーズ １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬としてのアダマンチル誘導体
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
ES2538714T3 (es) 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
JP2007254409A (ja) * 2006-03-24 2007-10-04 Taisho Pharmaceut Co Ltd イミダゾリジノン誘導体
WO2008044656A1 (fr) * 2006-10-06 2008-04-17 Taisho Pharmaceutical Co., Ltd. Dérivé d'imidazolidinone
ATE462696T1 (de) 2006-10-19 2010-04-15 Hoffmann La Roche Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
EP2308851A1 (en) 2006-10-19 2011-04-13 F. Hoffmann-La Roche AG Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes
KR101176699B1 (ko) 2006-10-19 2012-08-23 에프. 호프만-라 로슈 아게 아미노메틸-4-이미다졸
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.

Also Published As

Publication number Publication date
PE20080890A1 (es) 2008-06-28
CA2666489C (en) 2012-10-02
US20080103183A1 (en) 2008-05-01
EP2308851A1 (en) 2011-04-13
EP2104665A2 (en) 2009-09-30
TW200831088A (en) 2008-08-01
CL2007002972A1 (es) 2008-05-30
AU2007312391A1 (en) 2008-04-24
RU2439062C2 (ru) 2012-01-10
TWI339120B (en) 2011-03-21
CN101553474B (zh) 2013-02-27
KR20110079776A (ko) 2011-07-07
NO20091548L (no) 2009-05-05
MX2009003939A (es) 2009-05-11
WO2008046758A2 (en) 2008-04-24
AR063332A1 (es) 2009-01-21
CA2666489A1 (en) 2008-04-24
CN101553474A (zh) 2009-10-07
JP5079011B2 (ja) 2012-11-21
KR20090065535A (ko) 2009-06-22
KR101118410B1 (ko) 2012-04-23
RU2009118488A (ru) 2010-11-27
BRPI0717657A2 (pt) 2013-12-24
US8129423B2 (en) 2012-03-06
JP2010506876A (ja) 2010-03-04
IL197955A0 (en) 2009-12-24
WO2008046758A3 (en) 2009-06-11
AU2007312391B2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
IL197955A0 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
ZA200903286B (en) Hydantoin derivatives used as MMP Inhibitors
HK1101823A1 (en) Imidazole derivatives used as tafia inhibitors
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
HK1127354A1 (en) Heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors mek
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
IL193482A0 (en) Hydantoin based kinase inhibitors
TWI348908B (en) Imidazolidinone derivatives
HK1127342A1 (en) Substituted imidazole derivatives and there use as ptpase inhibitors
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
ZA200901127B (en) Aminoindazole urea derivatives
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
HK1124068A1 (en) 2-arylindole derivatives as mpges-1 inhibitors
SI1937673T1 (sl) Imidazolovi derivati kot inhibitorji TAFIa
GB0622472D0 (en) Novel heterocyclic derivatives
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA200806706B (en) Heterocyclic amides for use as pharmaceuticals
ZA200806993B (en) Hydantoin based kinase inhibitors
AU2014216020B9 (en) Heterocyclic compound and use thereof